Butyrolactone I – 5 mg

Brand:
Cayman
CAS:
87414-49-1
Storage:
-20
UN-No:
Non-Hazardous - /

Butyrolactone I is a secondary metabolite from A. terreus that acts as an ATP-competitive inhibitor of cyclin-dependent kinase 1 (Cdk1; IC50 = 20 μg/ml in PC-14 cells).{36048} It induces dose-dependent G2/M arrest, inhibits DNA synthesis, and decreases Cdk1 protein expression in vitro.{36048} Butyrolactone I has antitumor effects in non-small cell lung, small cell lung, and prostate cancer cell lines (mean IC50 = 50 μg/ml).{36048,36049} It inhibits in vitro Cdk1 phosphorylation of tau and in vivo phosphorylation of transcription factor E2F-1.{36050,36051} Additionally, exogenous application of butyrolactone I to A. terreus cultures increases biogenesis of the secondary metabolites lovastatin (Item No. 10010338) and conidiation in a quorum-sensing manner.{36052}  

 

Out of stock

SKU: 21765 - Category:

Description

A Cdk1 inhibitor (IC50 = 20 μg/ml in PC-14 cells); induces dose-dependent G2/M arrest, inhibits DNA synthesis, and decreases Cdk1 protein expression in vitro; has antitumor effects in non-small lung, small cell lung, and prostate cancer cell lines (average IC50 = 50 μg/ml); inhibits in vitro Cdk1 phosphorylation of tau; inhibits in vivo phosphorylation of transcription factor E2F-1; increases biogenesis of the secondary metabolite lovastatin and conidiation in A. terreus,


Formal name: (2R)-2,5-dihydro-4-hydroxy-2-[[4-hydroxy-3-(3-methyl-2-buten-1-yl)phenyl]methyl]-3-(4-hydroxyphenyl)-5-oxo-2-furancarboxylic acid, methyl ester

Synonyms: 

Molecular weight: 424.5

CAS: 87414-49-1

Purity: ≥95%

Formulation: A solid


Product Type|Biochemicals|Kinase Inhibitors|CDKs||Product Type|Biochemicals|Natural Products|Microbial Metabolites||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Cell Cycle|G2/M||Research Area|Cancer|Cell Signaling||Research Area|Cancer|Transcription Factors||Research Area|Neuroscience